Authors | Pub | N | Median Follow-up (months) | Hormone Therapy (%) | EBRT (%) | Bounce Def | Rate (%) | Time to onset (months) | Magnitude (ng/ml) | Duration (months) | Predictive factors |
---|---|---|---|---|---|---|---|---|---|---|---|
Aaltomaa [10] | 2009 | 444 | 81.6 | yes (18) | Yes (4) | ≥ 0.2 ng/ml | 13 | 19.2 | 1.4 | -- | Age < 65, risk group, PSA nadir < 0.5 |
Bostancic et al. [11] | 2007 | 164 | 65 | yes (37.2) | no | ≥ 0.2 ng/ml | 26.9 | 18.9 | 0.5 | 8.7 | Age,125 I >103 Pd * |
Cavanagh et al. [12] | 2000 | 591 | 55 | no | yes | ≥ 0.2 ng/ml | 35.8 | 24.8 | -- | -- | NC |
Ciezki et al. [13] | 2006 | 162 | 73 | yes (38.2) | no | ≥ 0.2 ng/ml | 46.3 | 15 | -- | -- | Age < 70 * |
Caloglu [26] | 2010 | 820 | 58 | Yes (22.2) | no | ≥ 0.2 ng/ml ≥ 0.4 ≥ 0.6 ≥ 0.8 | 30.1 19.6 12.8 9.5 | 17.4 16.3 16.2 15.7 | -- | -- | Age, N of PSAs |
Critz et al. [27] | 2003 | 1,011 | 72 | no | all | ≥ 0.1 ng/ml | 41 | 18 | 0.4 | 9 | Age |
Crook et al. [14] | 2007 | 275 | 44 | no | no | ≥ 0.2 ng/ml | 40 | 15.6 | 0.76 | 6.8 | Age * |
Das et al. [15] | 2002 | 186 | 33 | no | yes (25.8) | ≥ 15% | 62 | 26.4 | 0.6 | 12 | -- |
Kanai et al. [17] | 2009 | 86 | 32 | no | no | ≥ 0.4 ng/ml | 33 | 15 | 0.6 | -- | Age < 67, D90 > 180 Gy |
Kuban et al. [18] | 2006 | 2,693 | 63 | no | no | ≥ 0.2 ng/ml | 17 | -- | 0.9 | 14 | -- |
Hinnen et al. [16] | 2011 | 975 | 78 ¤ | Yes (19) | no | ≥ 0.2 ng/ml | 32.3 | 19.2 | -- | -- | -- |
Makarewicz et al * [19] | 2006 | 71 | 32 | no | Yes (100) | ≥ 0.2 ng/ml | 31 | 13.5 | 0.28 | -- | Age, i PSA, V200 |
McGrath et al [28]* | 2009 | 191 | 48 | Yes (46%) | no | ≥ 0.1 ng/ml ≥ 0.2 ng/ml ≥ 0.4 ng/ml ≥ 2 ng/ml | 44 34 21 3 | -- | 0.2 0.3 0.6 2.6 | 15 -- -- 25 | -- |
Merrick et al. [20] | 2003 | 218 | 46 | no | yes (57.1) | ≥ 0.2 ng/ml | 23.9 | 16.3 | 0.9 | 16 | Age, TNM, V150 PSA post brachy |
Mitchell et al. [21] | 2008 | 205 | 45 | no | no | ≥ 0.2 ng/ml | 37 | 14.8 | 0.91 | -- | Age |
Morita et al. [29] | 2004 | 200 | 35 | no | no | ≥ 0.1 ng/ml | 40 | 13 | 0.3 | -- | -- |
Patel et al. [22] | 2004 | 295 | 38 | yes (62.4) | no | ≥ 0.2 ng/ml | 28 | 19.4 | 0.5 | -- | Age < 65 * |
Pickles et al. [30] | 2006 | 449 | 48 | yes (70) | no | all | 84 | 13 | -- | -- | -- |
Satoh et al. [24] | 2008 | 388 | -- | no | no | ≥ 0.1 ng/ml ≥ 0.4 ng/ml ≥ 35% | 50.8 23.5 19.4 | -- | 0.4 | -- | -- |
Stock et al. [25] | 2003 | 373 | 48 | no | no | ≥ 0.1 ng/ml ≥ 0.4 ng/ml ≥ 35% | 31 17 20 | 19.5 19.5 20.5 | -- | -- | Age < 65, prostate volume > 35 cm3 (bounce > 0.4)* |
Thompson [31] | 2010 | 1,006 | 54 | Yes (65.7%) | no | +2 then nadir ≤ 0.5 ng/ml | 2.5 | 20.6 | -- | -- | Age |
2006 | 295 | 42 | yes (42.4) | no | ≥ 0.1 ng/ml ≥ 0.2 ng/ml ≥ 0.4 ng/ml | 55 49 32 | 19 | 0.8 | 11.2 | Age < 70, D90 > 200 Gy * | |
Zwahlen [34] | 2010 | 194 | 60 | no | no | ≥ 0.2 ng/ml ≥ 0.4 ng/ml ≥ 15% ≥ 35% | 50 34 11 9 | 14 14 16 15.5 | 05 0.8 1.9 2 | 12 13 18 21.5 | Age |
Mazeron (this study) | 2012 | 198 | 64 | no | no | ≥ 0.1 ng/ml ≥ 0.2 ng/ml ≥ 0.4 ng/ml ≥ 15% ≥ 35% | 48.5 35.9 25.8 52 36.4 | 17 | 0.6 | 14 | Age, PSA 6 weeks |